An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis
Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis
Sponsor: Insmed Incorporated
Listed as NCT05344508, this observational or N/A phase trial focuses on Non-Cystic Fibrosis Bronchiectasis and remains ongoing. Sponsored by Insmed Incorporated, it has been updated 15 times since 2026, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Dec 2025 — Present [monthly]
Approved For Marketing
Status: Available → Approved For Marketing
-
Aug 2025 — Dec 2025 [monthly]
Available
-
Jun 2025 — Aug 2025 [monthly]
Available
-
Mar 2025 — Jun 2025 [monthly]
Available
-
Dec 2024 — Mar 2025 [monthly]
Available
▶ Show 10 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Available
-
Jul 2024 — Sep 2024 [monthly]
Available
-
Mar 2024 — Jul 2024 [monthly]
Available
-
Dec 2023 — Mar 2024 [monthly]
Available
-
Sep 2023 — Dec 2023 [monthly]
Available
-
Jun 2023 — Sep 2023 [monthly]
Available
-
Feb 2023 — Jun 2023 [monthly]
Available
-
Nov 2022 — Feb 2023 [monthly]
Available
-
Sep 2022 — Nov 2022 [monthly]
Available
-
May 2022 — Sep 2022 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Insmed Incorporated
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.